Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group.
暂无分享,去创建一个
[1] E. Braunwald,et al. Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial , 1993 .
[2] M. Simoons,et al. Tailored Thrombolytic Therapy A Perspective , 1993, Circulation.
[3] J. Reiber,et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. , 1993, The New England journal of medicine.
[4] J O'Keefe,et al. A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .
[5] F. Van de Werf,et al. Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? European Cooperative Study Group. , 1993, European heart journal.
[6] F. Van de Werf,et al. Recombinant Tissue‐Type Plasminogen Activator and Immediate Angioplasty in Acute Myocardial Infarction: One‐Year Follow‐up , 1992, Circulation.
[7] E. Braunwald,et al. One‐Year Results of the Thrombolysis in Myocardial Infarction Investigation (TIMI) Phase II Trial , 1992, Circulation.
[8] J. Anderson,et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.
[9] J. Tijssen,et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.
[10] F. Van de Werf,et al. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.
[11] H. Lambertz,et al. THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.
[12] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.
[13] K. Lee,et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.
[14] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[15] M. Simoons,et al. IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.
[16] J L Ritchie,et al. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. , 1985, The New England journal of medicine.
[17] M. Weinstein,et al. Clinical Decision Analysis , 1980 .
[18] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[19] A. Muijtjens,et al. Estimation of circulatory parameters in patients with acute myocardial infarction. Significance for calculation of enzymatic infarct size. , 1979, Cardiovascular research.